title: Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma.
abstract: BACKGROUND
  To evaluate the efficacy and safety of latanoprost compared with timolol in the treatment of Asian patients with chronic angle-closure glaucoma (CACG).
  
  
  METHODS
  Relevant trials were identified through systematic searches of Medline, EMBASE, PubMed, Cochrane Library, Google Scholar and several Chinese databases. The main outcome measures included absolute and relative reduction of intraocular pressure (IOP) at mean, peak and trough from baseline, ocular adverse effects and systemic adverse events.
  
  
  RESULTS
  Seven randomized controlled trials with 685 patients were included. In comparison with timolol, latanoprost reduced absolute IOP in CACG patients by more than 2.3 mmHg (95%CI, 1.8∼2.9, P<0.01), 2.4 mmHg (95%CI, 1.9∼2.9, P<0.01) and 2.5 mmHg (95%CI, 1.6∼3.3, P<0.01) at mean, peak and trough, respectively. As for relative IOP, there is 9.0% (95%CI, 6.6∼11.4, P<0.01), 9.7% (95%CI, 7.6∼11.8, P<0.01), and 10.8% (95%CI, 7.4∼14.3, P<0.01) greater reduction among latanoprost users than among timolol users. The differences were statistically significant at all time points (1, 2, 4, 8, 12, and 24 weeks). More ocular adverse effects (OR = 1.49, 95% CI, 1.05∼2.10, P = 0.02) and less systemic adverse events (OR = 0.46, 95% CI, 0.25∼0.84, P = 0.01) were observed in latanoprost group in comparison with timolol group.
  
  
  CONCLUSIONS
  Compared with timolol, latanoprost was significantly more effective in lowering IOP of Asian patients with CACG, with higher risk of ocular adverse effects but lower risk of systemic adverse events, and might be a good substitute for CACG patients.
authors.affiliation: Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
authors.forename: Shi-Ming
authors.initials: SM
authors.lastname: Li
authors.affiliation: Department of Epidemiology and Health Statistics, Peking University School of Public Health, Beijing, China.
authors.forename: Ru
authors.initials: R
authors.lastname: Chen
authors.affiliation: Pfizer China, Beijing, China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Epidemiology and Health Statistics, Peking University School of Public Health, Beijing, China.
authors.forename: Zhi-Rong
authors.initials: ZR
authors.lastname: Yang
authors.affiliation: Department of Genetics, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Hai Dian District, Beijing, China.
authors.forename: Qiu-Ju
authors.initials: QJ
authors.lastname: Deng
authors.affiliation: Pfizer China, Beijing, China.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Zhong
authors.affiliation: Pfizer Global Pharmaceuticals, New York, New York, United States of America.
authors.forename: Moh-Lim
authors.initials: ML
authors.lastname: Ong
authors.affiliation: Department of Epidemiology and Health Statistics, Peking University School of Public Health, Beijing, China.
authors.forename: Si-Yan
authors.initials: SY
authors.lastname: Zhan
mesh_terms: D001208:Asia; D015812:Glaucoma, Angle-Closure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D000077338:Latanoprost; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012449:Safety; D013999:Timolol / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D013999:Timolol